A 5-year Prospective and Observational Study to Evaluate the Effectiveness of Nucleos(t)Ide Analogs (NUC) Therapy Among Chronic Hepatitis B (CHB) Patients Naive to NUC in Real World Practice at Hospitals in Tier 2 Cities in China (the EVOLVE Study)

Trial Profile

A 5-year Prospective and Observational Study to Evaluate the Effectiveness of Nucleos(t)Ide Analogs (NUC) Therapy Among Chronic Hepatitis B (CHB) Patients Naive to NUC in Real World Practice at Hospitals in Tier 2 Cities in China (the EVOLVE Study)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Feb 2016

At a glance

  • Drugs Entecavir (Primary) ; Adefovir dipivoxil; Antivirals; Lamivudine
  • Indications Hepatitis B
  • Focus Registrational; Therapeutic Use
  • Acronyms EVOLVE
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 17 Feb 2016 Planned End Date changed from 1 Apr 2016 to 1 Apr 2019as per ClinicalTrials.gov record.
    • 17 Feb 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2019 as per ClinicalTrials.gov record.
    • 23 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top